Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Cocrystal Pharma Q3 2026 Results: Net Loss of $3.44M, Loss Widens

Cocrystal Pharma reported a net loss of $8.9 million for the nine months ended September 30, 2026, compared to $6.4 million in the prior year, driven by increased research and development expenses. The company raised substantial doubt about its ability to continue as a going concern, noting that its $4.9 million in cash and restricted cash is insufficient to fund operations for the next 12 months.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue0.1—
Net income-3.4-2.0
EPS (diluted, $ a share)$-0.20$-0.19

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Source

10-Q filed with the SEC, NASDAQ: COCP. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Cocrystal Pharma, Inc.: key numbers

Share price
$0.9777Close, Nov 16
Market cap
$18.8M
Shares outstanding
19.26MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.